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ing intravenous administration of P4, a short-term and re-
versible period of mild fluctuations in heart rate was ob-
served. Administration of P4NO revealed no changes in 
either heart rate, or blood pressure.  Conclusion: All of the 
investigated parameters revealed less anticholinergic ef-
fects for P4NO compared to P4. Under the experimental con-
ditions described above, it may be assumed that P4NO be-
haves as a substance with poor anticholinergic effects with 
respect to side effects. As expected, P4 showed anticholin-
ergic effects on bladder contraction and salivation. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 In urology, substances with anticholinergic properties 
are administered in the treatment of all types of bladder 
overactivity. The therapeutic effect is based on competi-
tive inhibition of the postganglion and intramural mus-
carinic receptors of the urinary bladder. This causes the 
natural neurotransmitter acetylcholine to assert less in-
fluence, thus suppressing bladder contraction.
 Anticholinergic therapy is the first-line treatment op-
tion for patients with overactive bladder. Different drugs 
are available (e.g. darifenacin  [1] , oxybutynin  [2] , propiv-
erine (P4)  [3] , solifenacin  [4] , tolterodine  [5] , trospium 
chloride  [6] ).
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 Abstract 
 Purpose: The objective of this study was to evaluate the
influence of propiverine-HCl (P4) and propiverine-N-oxide 
(P4NO), one of the major metabolites of P4, on bladder con-
traction in a standardized in vivo model. Additionally, sali-
vary flow measurements enabled the evaluation of hyposal-
ivation, one of the most predominant anticholinergic side 
effects.  Materials and Methods: Ten male mini pigs were 
anesthetized. P4 (0.4 mg/kg b.w.) and P4NO (0.422 mg/kg
b.w.) were administered intravenously. Bladder contractions 
were induced through sacral anterior root stimulation and 
cystometrogram evaluation was performed. For stimula-
tion-induced salivary flow measurements, the lingual nerve 
was exposed for neurostimulation. The effects of P4 and 
P4NO on stimulation-induced bladder contraction and sali-
vation were evaluated in 5 mini pigs, respectively.  Results: 
In all experiments, for each animal reproducible intravesical 
pressure values (Pves) were elicited during sacral anterior 
root stimulation before administration of the study drug. Af-
ter administration of P4, Pves decreased by 64% whereas 
P4NO decreased Pves by 28%. Inhibition of salivary flow with 
P4 and P4NO was 71 and 32%, respectively. Directly follow-
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 Oxybutynin has both an antimuscarinic and a direct 
muscle-relaxant effect. P4 is a smooth-muscle-relaxing 
agent with anticholinergic and calcium-antagonistic 
properties demonstrated in in vivo and in vitro studies. 
Darifenacin, solifenacin, tolterodine and trospium chlo-
ride are pure antimuscarinics. Although clinical efficacy 
of some of these drugs has been proven to be high, its use 
is limited by antimuscarinic adverse effects, possibly re-
lated to active metabolites.
 Most anticholinergic drugs metabolize in the liver into 
more or less active metabolites. The extent to which the 
active metabolites contribute to pharmacological effects 
at the target tissue depends on their affinity to the recep-
tors. In the case of some anticholinergic drugs, active me-
tabolites might contribute to the overall clinical profile of 
the drug. Tolterodine and oxybutynin, for example, are 
extensively metabolized in the liver to the active metabo-
lites 5-hydroxymethyl-tolterodine and N-desethyloxy-
butynin, respectively  [7] . P4 is also metabolized in the 
liver and propiverine-N-oxide (P4NO) is the principal 
metabolite in human blood  [8] . Although the effects of P4 
metabolites have extensively been studied in vitro  [9, 10] , 
sparse information of in vivo action of P4NO is avail-
able.
 The objective of this study was to evaluate the influ-
ence of P4 and P4NO on electrostimulation-induced 
bladder contraction in a standardized mini pig model 
 [11] . Additionally, salivary flow measurements enabled 
the evaluation of hyposalivation, one of the most pre-
dominant anticholinergic side effects.
 Materials and Methods 
 Ten adult male Göttinger mini pigs (b.w. 25–37 kg, Ellegaard 
Mini Pigs ApS, Denmark) were anesthetized by i.m. administra-
tion of 200 mg ketamine (Intervet, Unterschleißheim, Germany) 
and 15 mg midazolam. The animal was intubated and connected 
to an artificial respirator and anesthesia was maintained with 
2.3% isoflurane (Abbott, Wiesbaden, Germany) and an oxygen 
supply of 40%. Moreover, 0.3 mg/kg/h piritramide (Janssen Cilag, 
Neuss, Germany) was administered continuously intravenously 
via an infusion pump. The carotid artery was cannulated for 
blood pressure control and the jugular vein for perioperative in-
fusion with Ringer’s solution and administration of the study 
drugs (P4 and P4NO; Apogepha GmbH, Dresden, Germany). The 
lingual nerves were exposed and a cuff electrode was placed 
around the nerve and connected to an external neurostimulator.
 The urinary bladder was exposed by a mid-abdominal inci-
sion and a catheter was inserted into the bladder via a cystostomy 
for cystometrographic measurements with computerized urody-
namic equipment (Wiest 8000, Unterhachingen, Germany). The 
bladder was filled with 200 ml physiological saline (approx. 2/3 of 
maximal bladder capacity). Both ureters were cannulated and bi-
lateral ureterocutaneostomy was performed in order to maintain 
a constant bladder volume during the duration of the study. The 
posterior urethra was ligated in order to avoid urine leakage dur-
ing sacral anterior root stimulation (SARS).
 Laminectomy and identification of the sacral roots followed 
closure of the abdomen and funneling the connecting wires of
the electrodes to the body surface. A modified Brindley electrode 
(Finetech, London, UK) was placed at the sacral anterior root S2 
and connected to an external neurostimulator.
 Individual electrostimulation of the lingual nerve and the 
sacral anterior root S2 with standardized stimulation parameters 
was carried out after completion of the operative procedures. In 
addition, stimulation-induced salivation of the submandibular 
gland was evaluated by a pad test. The pad was weighed before 
and after stimulation in order to assess the amount of salivation 
adsorbed during stimulation of the lingual nerve (3 min). A re-
covery period of at least 20 min elapsed between each neurostim-
ulation to avoid neurostimulation-induced fatigue of the detrusor 
muscle and the submandibular glands. Blood pressure and heart 
rate (HR) were continuously monitored throughout the entire 
study. During the study, hypothermia was prevented by constant 
maintenance of the core body temperature with an electric blan-
ket (37 ° C) and infusion with warmed Ringer’s solution.
 The effects of P4 (0.4 mg/kg b.w.) and P4NO (0.422 mg/kg
b.w.) on stimulation-induced bladder contraction and salivation 
were evaluated in five mini pigs, respectively. The chosen dose of 
P4NO is molar equivalent to the dose of P4. Drugs were dissolved 
in 20 ml 0.9% physiological saline and were given intravenously 
within 60 s (jugular vein). 40 min after administration of the sub-
stance or after at least two consecutive neurostimulations, atro-
pine (4 mg) was also administered intravenously following SARS 
and neurostimulation of the lingual nerve ( fig. 1 ).
 The following stimulation parameters were used for SARS: bi-
phasic rectangular pulses, peak to peak amplitude 4 mA, duration 
of plateau phase 200   s, stimulation frequency 20 Hz, total time 
of each stimulation 15 s.
 The following stimulation parameters were used for stimula-
tion of the lingual nerve: biphasic rectangular pulses, peak to 
peak amplitude 4 mA, duration of plateau phase 2 ms, stimulation 
frequency 5 Hz, total time of each stimulation 3 min.
 The protocol was approved by the institutional animal care 
and use committee of the University Hospital Mannheim, Karl 
Ruprecht University Heidelberg, and was in line with EU guide-
lines. All values are expressed as the mean  8 SEM. Statistical 
significance was determined by Student’s t test with p  ! 0.05 con-
sidered statistically significant.
 Results 
 Bladder Pressure  
 In all experiments, for each animal reproducible intra-
vesical pressure values (Pves) were elicited during SARS 
before administration of the model drugs ( fig. 2 ).
 Forty minutes after i.v. administration of P4,  the 
neurostimulation-induced rise in Pves dropped from 
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42.0 cm H 2 O before drug administration to 16.8 cm H 2 O 
(p = 0.056). After additional administration of atropine, 
stimulation-induced Pves dropped further to 5.4 cm H 2 O 
(p  ! 0.05).
 Forty minutes after i.v. administration of P4NO, 
neurostimulation-induced rise in Pves dropped from 
31.8 to 25.0 cm H 2 O (p = 0.077). After additional admin-
istration of atropine, stimulation-induced Pves further 
decreased to 10.8 cm H 2 O (p  ! 0.05) ( table 1 ).
 Salivation  
 Before administration of the study drug, stimulation-
induced salivation was reproducible for each animal in 
all studies ( table 2 ). In one experiment the electrodes 
were dislocated (P4NO) and in another one technical fail-
ure caused inadequate evaluation of salivary flow 
(P4NO).
 After administration of P4, neurostimulation-induced 
salivary flow decreased from 109.4 mg/3 min to 50 mg/3 
min (p  ! 0.05). Additional intravenous administration of 
atropine induced a further inhibition of salivary flow to 
4.2 mg/3 min (p  ! 0.05).
 Under the influence of P4NO, neurostimulation-in-
duced salivary flow decreased from initial 53.3 mg/3 min 
to 39.3 mg/3 min (p = 0.184). After atropine, stimulation-
induced salivary flow dropped further to 19.7 mg/3 min; 
however, this decrease was not significant (p = 0.108).
 HR and Blood Pressure  
 During the operative procedures, all animals were sta-
ble in terms of blood pressure and HR ( tables 3 ,  4 ). Di-
rectly following intravenous administration of P4, a sig-
nificant increase in HR at a mean of 17% of the initial 
value was observed during the first 10 min (p  ! 0.05). The 
Operative procedure
1st stimulation
2nd stimulation
3rd stimulation
2nd stimulation
after drug application
Administration of the
P4/P4NO/atropine
1st stimulation
after drug application
Administration of
atropine
Final stimulation after
administration of atropine
End of the study
20 min
20 min
20 min
20 min
20 min
 Fig. 1.  Flow chart of the stimulation 
study. 
 Effects of Propiverine on Bladder 
Function and Salivation 
Urol Int 2008;81:468–473 471
HR returned to baseline value after 20 min. This increase 
in HR was not observed in the P4NO group.
 After administration of the study drugs, there was no 
change in mean arterial pressure (MAP) compared with 
baseline: 61.8 versus 62.8 mm Hg for P4 and 64.6 versus 
64.4 mm Hg for P4NO. MAP was calculated using the 
formula: MAP (mm Hg) = (systolic + 2  ! diastolic)/3. 
Gas analysis throughout the study showed no relevant 
changes.
 Discussion 
 In a porcine model, electrostimulation of the sacral 
roots responsible for bladder contraction leads to detru-
sor activation with consecutive rise in bladder pressure. 
This stimulation-induced rise in bladder pressure can be 
urodynamically evaluated and objectively quantified. 
Standardized stimulation parameters result in reproduc-
ible, stimulation-induced bladder contractions suitable 
for pharmacological evaluation of drug effects on bladder 
contraction  [12] . In this study, the sacral root S2 was stim-
ulated to evoke neurogenic-induced bladder contrac-
tions. Further expansion of the porcine study procedure 
makes the investigation of typical anticholinergic side ef-
fects such as hyposalivation also possible  [11, 13] .
 In this experimental set-up, the study drugs were giv-
en intravenously. Therefore, first-pass metabolization in 
the liver and gut is negligible. This makes the presented 
model suitable for comparative investigations of a parent 
drug and its metabolites with respect to anticholinergic 
effects on the detrusor muscle and on salivary glands.
 The therapeutic effect of P4 is due to inhibition of cal-
cium influx into smooth muscle cells and competitive an-
tagonism with acetylcholine at muscarinic receptor sites 
 [3] . P4 undergoes extensive first-pass metabolism (N-ox-
Table 1. Stimulation-induced bladder pressure
Before
cm H2O
After
cm H2O
Atropine
cm H2O
P4
No. 1 50 (100) 18 (36) 3 (6)
No. 2 62 (100) 6 (10) 4 (8)
No. 3 25 (100) 17 (68) 4 (16)
No. 4 37 (100) 10 (27) 4 (11)
No. 5 36 (100) 33 (92) 12 (24)
Mean8SEM 42.086.4 16.884.6 5.481.7
P4NO
No. 1 47 (100) 45 (96) 20 (43)
No. 2 14 (100) 10 (71) 5 (36)
No. 3 22 (100) 16 (73) 7 (32)
No. 4 18 (100) 14 (78) 6 (33)
No. 5 58 (100) 40 (69) 16 (28)
Mean8SEM 31.888.7 25.087.3 10.883.0
Figures in parentheses are percentages.
Table 2. Stimulation-induced salivary flow
Before
mg/3 min
After
mg/3 min
Atropine
mg/3 min
P4
No. 1 168 (100) 66 (39) 2 (1)
No. 2 68 (100) 20 (29) 10 (15)
No. 3 160 (100) 110 (69) 5 (3)
No. 4 131 (100) 34 (26) 2 (2) 
No. 5 20 (100) 20 (100) 2 (10)
Mean8SEM 109.4828.4 50.0817.2 4.281.6
P4NO
No. 1 88 (100) 60 (68) 50 (57)
No. 2 60 (100) 54 (90) 8 (13)
No. 3 – – –
No. 4 – – –
No. 5 12 (100) 4 (33) 1 (8)
Mean8SEM 53.3822.2 39.3817.0 19.7815.3
Figures in parentheses are percentages.
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 Fig. 2. Representative course of bladder pressure and salivary flow 
of one study with P4. 
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idation, O- and/or N-dealkylation). Only 3% of the drug 
is recovered unchanged in the urine and bile after oral 
administration. The metabolite P4NO can be recovered 
from the human urine for 20% of the original dose  [8] .
 In vivo effects of anticholinergic drugs depend on re-
ceptor affinity and on free plasma concentration. Recent 
work has shown that P4NO has lower affinity for musca-
rinic receptors than P4  [14] . These data obtained from in 
vitro studies were in accordance with the results of our 
functional in vivo study. Furthermore, it is known that 
the free plasma concentration is higher for P4NO than for 
P4  [15] , and therefore anticholinergic effects should be 
less pronounced compared to P4.
 The results of the present study demonstrate that the 
principal metabolite of P4, P4NO, possesses less anticho-
linergic properties. With respect to the inhibition of 
stimulation-induced bladder contraction, the effect of 
P4NO was maximal 30%, whereas maximal inhibition of 
P4 was 90%. Salivation flow evaluation revealed similar 
results, although in the group with P4NO, two measure-
ments failed due to technical problems. The variations in 
initial stimulation-induced Pves and salivation might be 
due to interindividual variations of the nervous and/or 
urinary system in each animal. Nevertheless, all investi-
gated parameters were reproducible in each animal be-
fore the test substance was administered.
 P4 failed to inhibit stimulation-induced Pves and sali-
vary flow in one pig. On the other hand, the HR of these 
animals did react appropriately after application of the 
study drug. The reasons for this are unclear. An explana-
tion could be that the lower urinary tract of these animals 
was insensitive to P4 since additionally administration of 
atropine inhibited Pves and salivation adequately.
 Contrary to P4 and atropine, no relevant changes in 
HR or blood pressure were observed after administration 
of P4NO. A temporary rise in HR was observed immedi-
ately after intravenous administration of P4 and atropine. 
However, this returned to normal within 25 min.
 Recently, in vitro studies suggested that the metabolite 
M5 (the N-oxide of propiverine) reduces detrusor con-
tractions elicited by electric field stimulation  [9] . This 
seems to be in contrast to our results and might be ex-
plained with differences in experimental setup. The re-
sults of the above-mentioned study are derived from in 
vitro studies on urothelium-denuded detrusor strips. 
Furthermore, we used a single dose and a weaker inhibi-
tion might reflect this. Therefore, comparison of the data 
is difficult due to experimental differences. Furthermore, 
the concentration used in in vitro studies cannot be trans-
ferred to an in vivo situation.
 Anticholinergic drug therapy typically does not sup-
press detrusor overactivity but mainly increases bladder 
capacity, compliance and volume of first unstable con-
traction  [16] . Furthermore, urodynamic studies in hu-
mans cannot unequivocally demonstrate a decrease in 
maximum bladder pressure. However, some groups re-
Table 3. Heart rate
Before
min–1
After
min–1
Atropine
min–1
P4
No. 1 113 (100) 135 (119) 139 (123)
No. 2 102 (100) 120 (118) 129 (126)
No. 3 118 (100) 136 (115) 144 (122)
No. 4 87 (100) 104 (120) 124 (143) 
No. 5 54 (100) 63 (117) 66 (122)
Mean8SEM 94.8811.5 111.6813.4 120.4814.1
P4NO
No. 1 67 (100) 67 (100) 66 (99)
No. 2 86 (100) 87 (101) 89 (103)
No. 3 110 (100) 104 (95) 110 (100)
No. 4 88 (100) 90 (102) 103 (117)
No. 5 66 (100) 67 (101) 67 (101)
Mean8SEM 83.488.0 83.087.1 87.089.0
Figures in parentheses are percentages.
Table 4. Mean arterial pressure 
Before
mm Hg
After
mm Hg
Atropine
mm Hg
P4
No. 1 47 (100) 48 (102) 51 (109)
No. 2 80 (100) 82 (102) 80 (100)
No. 3 67 (100) 68 (101) 54 (81)
No. 4 66 (100) 67 (101) 75 (136) 
No. 5 49 (100) 49 (100) 53 (108)
Mean8SEM 61.886.2 62.886.4 62.686.2
P4NO
No. 1 50 (100) 51 (102) 43 (86)
No. 2 80 (100) 80 (100) 81 (101)
No. 3 64 (100) 65 (102) 63 (98)
No. 4 90 (100) 88 (98) 78 (87)
No. 5 39 (100) 38 (97) 40 (103)
Mean8SEM 64.689.4 64.489.2 61.088.6
Figures in parentheses are percentages.
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ported a change in maximum bladder pressure due to 
anticholinergics  [17, 18] . In these studies, the maximum 
detrusor pressure was lowered significantly in the P4 
group from 56.8 to 37.8 cm H 2 O and 43.8 to 27.1 cm H 2 O, 
respectively. Moreover, the latter studies reported a sup-
pression of phasic detrusor overactivity by 63%. The 
bladder contraction evoked in our study is elicited by 
stimulating the sacral micturition center and therefore is 
comparable with maximum bladder contraction. In our 
study, maximum bladder contraction was suppressed by 
P4 by 60%.
 In the presented animal model, only the efferent mo-
tor nerves were activated to induce bladder contraction, 
while the afferent pathway, which is believed to be in-
volved in the pathogenesis of detrusor overactivity, was 
excluded. Recent studies showed that several anticholin-
ergics might modulate bladder function through afferent 
nerve fibers  [19, 20] , and it cannot be excluded that P4NO 
in a chronic animal model might influence bladder func-
tion. However, an acute inhibitory effect of P4NO on ef-
ferent detrusor activation could not be demonstrated in 
this study.
 In summary, all of the investigated parameters re-
vealed less anticholinergic effects for P4NO compared to 
P4. Under the experimental conditions described above, 
it may be assumed that P4NO behaves as a substance with 
poor anticholinergic effects with respect to side effects. 
As expected, P4 showed anticholinergic effects on blad-
der contraction and salivation.
 This study provides information about in vivo efficacy 
of P4 and its principal metabolite P4NO and is probably 
more elucidating and representative than investigation of 
strips.
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